Get started
Verona Pharma plc Sponsored ADRVerona Pharma plc Sponsored ADRVerona Pharma plc Sponsored ADR

Verona Pharma plc Sponsored ADR

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Forecast Seasonals

I9SA trade ideas

Verona Pharmaceuticals (VRNA) Analysis Company Overview: Verona Pharmaceuticals specializes in treatments for respiratory diseases. The company recently received FDA approval for its inhaled non-steroidal COPD treatment, Ohtuvayre. Chronic Obstructive Pulmonary Disease (COPD) affects approximately 16 million Americans and is a leading cause of death. Key Highlights: FDA Approval: Ohtuvayre has demonstrated strong efficacy and safety in late-stage trials. Market Potential: Analyst estimates suggest peak sales could reach $3.6 billion. Launch Strategy: Verona plans to deploy around 100 sales reps targeting 15,000 physicians for the treatment's rollout. Investment Outlook: Bullish Outlook: We are bullish on NASDAQ:VRNA above the $18.00-$19.00 range. Upside Potential: With an upside target set at $29.00-$30.00, Verona Pharmaceuticals is poised for significant growth driven by Ohtuvayre's market potential and the large COPD patient population. 📈🌬️ Consider Verona Pharmaceuticals for investment opportunities in the respiratory treatment space! #VRNA #COPD 💊🚀
NASDAQ:VRNALong
by Richtv_official
Prepare for a new Pharma Cycle: Verona PharmaNASDAQ:VRNA is developing novel treatments to enhance the lives of those affected by chronic lung conditions. Recently their medication against the common disease called COPD got approved. 600 million people worldwide suffer from this disease, the market is huge . The Company is led by an experienced management team with an established track record in the discovery, clinical development and commercialization of respiratory therapeutics. The revenue of this medication is expected to grow from 9 million dollars 2024 to 740 million dollars 2027 . The chart looks good as well, the price broke over a midterm resistance and turned it into support. Beforehand a Double-Bottom formed, indicating a Target of around 30 dollars . If a new Pharma- and Biotech-Cycle starts, Verona could rise to 75 dollars by the beginning of 2025 .
NASDAQ:VRNALong
by HenrikDaCrypto
VRNA Three Falling Peaks (bearish)I found this pattern at tickeron website with the following data: STATUS = Confirmed CURRENT CONFIDENCE = 84% TARGET (EXIT) PRICE = 3.84 USD BREAKOUT (ENTRY) PRICE = 6.60 USD DISTANCE TO TARGET PRICE = 39.95% EMERGED ON = Aug 19, 12:00 PM (EDT) CONFIRMED ON = Sep 03, 01:03 PM (EDT) WITH CONFIDENCE LEVEL = 98% The Three Falling Peaks pattern forms when three minor Highs (1, 3, 5) arrange along a downward­-sloping trend line. This pattern often emerges at the end of a rising trend, when a security slowly rolls over. It potentially indicates sellers moving ­in to replace buyers, which pushes the price lower. Trade idea If the price breaks out from the bottom pattern boundary, day traders and swing traders should trade with the DOWN trend. Consider selling the security short or buying a put option at the downward breakout price level. To identify an exit, compute the target price by subtracting the pattern’s height (maximum price minus minimum price within the pattern) from the breakout level ­ the lowest low. When trading, wait for the confirmation move, which is when the price moves below the breakout level. To limit potential loss when price suddenly goes in the wrong direction, consider placing a stop order to buy back a short position or sell a put option at or above the breakout price.
NASDAQ:VRNAShort
by AlTorress
1
200 Million in Oversubscribed Private Placement and SubscriptionVerona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription Funding to support Phase 3 ENHANCE clinical program in COPD The Financing comprises a private placement of 39,090,009 of the Company’s American Depositary Shares (“ADSs”), each representing eight ordinary shares of the Company (“Ordinary Shares”), at a price of $4.50 per ADS, and 43,111,112 of the Company’s Ordinary Shares at the equivalent price per Ordinary Share, being £0.45 or $0.5625 Verona Pharma intends to use the net proceeds from the Financing primarily to fund its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) in chronic obstructive pulmonary disease (COPD) and for general corporate purposes. The Phase 3 clinical trials are planned to start later in 2020. With this financing we plan to initiate our Phase 3 ENHANCE clinical trials later this year and expect to support our programs into 2023. www.veronapharma.com The treatment is different to anything currently out on the market for COPD in that it has a dual-action. Ensifentrine has not shown side effects such as nausea, vomiting and weight loss, that halted previous attempts to develop similar drugs. The market liked this strategy, alongside a good data package from the phases I and II of clinical trials. So highly regarded industry names such as RA Capital, one of America’s leading biotech investors, backed the phase III because they see potential for success. Even if you see more positive sentiment towards healthcare, it still depends on the quality of the individual companies. In this case Verona had a large data set, a clear path forward agreed with the regulator and clear inflexion points. www.proactiveinvestors.co.uk
NASDAQ:VRNA
by AlenCiken